Press Releases Items Per Page 102550 Year None202020192018201720162015201420132012201120102007 07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias 06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference 05.14.19 Syndax to Present at the UBS Global Healthcare Conference 05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update 04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting 03.27.19 Syndax Announces $26.2 Million Offering of Common Stock and Warrants 03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update 03.06.19 Syndax to Present at the Cowen 39th Annual Health Care Conference 02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 01.07.19 Syndax Highlights 2019 Clinical and Corporate Outlook Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019
04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting
03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
02.28.19 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
02.27.19 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
